Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Connect Biopharma Holdings (CNTB) EBIT Margin (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed EBIT Margin for 2 consecutive years, with 110481.25% as the latest value for Q3 2025.

  • Quarterly EBIT Margin fell 10934540.0% to 110481.25% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 90740.62% through Dec 2025, down 9065438.0% year-over-year, with the annual reading at 90740.62% for FY2025, 9065438.0% down from the prior year.
  • EBIT Margin hit 110481.25% in Q3 2025 for Connect Biopharma Holdings, down from 27966.67% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 56.58% in Q2 2024 to a low of 110481.25% in Q3 2025.